Doxoruba Getwell Pharmaceuticals को ब्रान्ड परिवार हो, नेपालमा बिक्री हुन्छ। NepalDoc सूचीमा यसका २ वटा उत्पादन छन्, सबै Doxorubicin Hydrochloride।
Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer, for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma…
From the U.S. FDA-approved label for Doxorubicin Hydrochloride. Full label: DailyMed.
Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer, for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.
From the U.S. FDA-approved label for Doxorubicin Hydrochloride. Full label: DailyMed.
Single agent: 60 to 75 mg/m 2 given intravenously every 21 days, In combination: 40 to 75 mg/m 2 given intravenously every 21 to 28 days, Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy, Reduce dose in patients with hepatic impairment 2.1 Recommended Dosage for Adjuvant Breast Cancer The recommended dosage of Doxorubicin Hydrochloride Injection is 60 mg/m 2 administered as an intravenous bolus on day 1 of each 21-day treatment cycle, in combination with cyclophosphamide, for a total of four cycles.
Directions from the U.S. FDA-approved label for Doxorubicin Hydrochloride — your doctor or pharmacist may advise differently.
Doxorubicin Hydrochloride Injection are contraindicated in patients with: Severe myocardial insufficiency, Recent (occurring within the past 4–6 weeks) myocardial infarction, Severe persistent drug-induced myelosuppression, Severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL), Severe hypersensitivity reaction to doxorubicin hydrochloride, including anaphylaxis, Severe myocardial insufficiency, Recent myocardial infarction, Severe persistent drug-induced myelosuppression, Severe hepatic impairment, Severe hypersensitivity to doxorubicin hydrochloride
Excerpt from the U.S. FDA-approved label for Doxorubicin Hydrochloride. Talk to a pharmacist or doctor before use.
Radiation-Induced Toxicity: Can be increased by the administration of Doxorubicin Hydrochloride Injection. Radiation recall can occur in patients who receive Doxorubicin Hydrochloride Injection after prior radiation therapy., Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and on the use of effective contraception. Advise males with female partners of reproductive potential to use effective contraception. Advise males with pregnant partners to use condoms.
Warnings and precautions excerpt from the U.S. FDA-approved label for Doxorubicin Hydrochloride — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are described elsewhere in the labeling., Cardiomyopathy and Arrhythmias, Secondary Malignancies, Extravasation and Tissue Necrosis, Severe Myelosuppression, Tumor Lysis Syndrome, Radiation Sensitization and Radiation Recall The most common (>10%) adverse reactions are alopecia, nausea and vomiting. To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc.
Excerpt from the U.S. FDA-approved label for Doxorubicin Hydrochloride — not a complete list. Talk to a pharmacist or doctor about side effects.
७ ब्रान्ड · ४ निर्माता — NepalDoc सूचीमा — पूरै Doxorubicin Hydrochloride गाइड हेर्नुहोस् →
Store all vials at 2°C to 8°C (36°F to 46°F). Protect from light. Storage of Doxorubicin Hydrochloride Injection under refrigerated conditions can result in the formation of a gelled product. Place gelled product at room temperature for 2 to 4 hours to return the product to a slightly viscous, mobile solution.
Storage information from the U.S. FDA-approved label for Doxorubicin Hydrochloride.
Doxoruba 10 के हो?
Doxoruba 10mg Injection भनेको Doxorubicin Hydrochloride औषधि हो, Getwell Pharmaceuticals ले बनाएको। यो 10mg Injection रूपमा पाइन्छ।
Doxoruba 10 को सामान्य नाम के हो?
Doxoruba 10 को सामान्य नाम Doxorubicin Hydrochloride हो।
नेपालमा Doxorubicin Hydrochloride का कुन कुन ब्रान्ड उपलब्ध छन्?
NepalDoc सूचीमा Doxorubicin Hydrochloride का ७ वटा ब्रान्ड छन्, ४ निर्माताबाट — जसमा Adriamycin 50mg Injection, adriamycin 10mg Injection, adriamycin 50mg Injection, Adrim 10mg Injection, Adrim 50mg Injection, Doxoruba 50mg Injection पर्छन्।
Doxoruba 10 को मूल्य नेपालमा कति हो?
NepalDoc ले औषधिको मूल्य सूचीबद्ध गर्दैन। मूल्य हरेक फार्मेसीले आफैं तय गर्छ र समयसँगै परिवर्तन हुन्छ — यो पृष्ठले नेपालमा बिक्री हुने ब्रान्ड, यसको सामान्य नाम, निर्माता, शक्ति र प्याक विवरण पुष्टि गर्छ, ताकि तपाईं आफ्नो फार्मेसीमा मूल्य विश्वस्त भएर सोध्न सक्नुहोस्।
यो पृष्ठ सामान्य जानकारीका लागि मात्र हो, चिकित्सकीय सल्लाह होइन। औषधिको विवरण माथि उल्लेखित स्रोतहरूबाट आएको हो र परिवर्तन हुन सक्छ — प्रयोग गर्नुअघि डाक्टर वा फार्मासिस्टसँग औषधि, शक्ति र मात्रा पुष्टि गर्नुहोस्। सूचीमा हुनुले कुनै फार्मेसीमा औषधि उपलब्ध छ भन्ने ग्यारेन्टी दिँदैन।
नेपालडकका सबै खण्ड, एकै ठाउँमा।